• Thumbnail for Fingolimod
    Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, used for the treatment of multiple sclerosis. Fingolimod is a sphingosine-1-phosphate...
    27 KB (2,574 words) - 15:29, 18 October 2024
  • Thumbnail for Sphingosine-1-phosphate receptor modulator
    multiple sclerosis (MS). The most well-known compound in this class is fingolimod (FTY720), which was the first oral disease-modifying therapy approved...
    14 KB (1,555 words) - 16:58, 26 October 2024
  • Sphingolipidoses General structures of sphingolipids Dimethylsphingosine Fingolimod Radin N (2003). "Killing tumours by ceramide-induced apoptosis: a critique...
    4 KB (220 words) - 20:12, 19 July 2024
  • Thumbnail for Diethyl acetamidomalonate
    pharmaceutical formulations, particularly in the cases of active ingredients like fingolimod, which is used to treat multiple sclerosis. A notable method for synthesizing...
    10 KB (994 words) - 06:26, 12 November 2023
  • Thumbnail for Isaria sinclairii
    nymphs of cicadas. It produces myriocin, from which the synthetic drug fingolimod, a treatment for multiple sclerosis, was developed. Isaria sinclairii...
    8 KB (683 words) - 16:18, 10 January 2024
  • Thumbnail for Demyelinating disease
    remyelination after injury or disease. Immunomodulatory drugs such as fingolimod have been shown to reduce immune-mediated damage to the CNS, preventing...
    24 KB (2,696 words) - 16:13, 4 November 2024
  • Thumbnail for Ozanimod
    established through the clinical work performed during development of fingolimod (trade name Gilenya), a non‐selective S1P modulator.[better source needed]...
    34 KB (3,309 words) - 16:05, 18 October 2024
  • fumarate itself, (Bafiertam), approved in April 2020. Four S1P modulators: Fingolimod (Gilenya), an oral treatment and the first oral therapy approved for multiple...
    83 KB (9,405 words) - 11:49, 23 August 2024
  • Thumbnail for Ceramide
    5541 CYM-50260 CYM-50308 Dihydro-S1P (sphinganine 1-phosphate) Fingolimod Fingolimod phosphate KRP-203 Mocravimod Ozanimod Phyto-S1P Ponesimod RP-001...
    30 KB (3,360 words) - 02:17, 7 November 2024
  • Thumbnail for Progressive multifocal leukoencephalopathy
    during a 4-year course of dimethyl fumarate, developed PML and died. Fingolimod (Gilenya) was approved in 2010 by the FDA for MS. In 2015, the first case...
    23 KB (2,414 words) - 09:27, 7 November 2024
  • degeneration. There are 5 types of Sphingosine-1-phosphate receptor. The drug fingolimod (FTY720), which agonizes the S1P receptor, prevents autoimmune lymphocytes...
    25 KB (2,659 words) - 02:02, 10 July 2024
  • Thumbnail for Multiple sclerosis
    roughly equivalent to that of adults. The role of some newer agents such as fingolimod, teriflunomide, and dimethyl fumarate, is not yet entirely clear. Making...
    170 KB (18,177 words) - 15:22, 11 November 2024
  • in Penicillium stoloniferum. Thermophilic fungi were the source of the fingolimod precursor myriocin. Aspergillus synthesizes immunosuppressants gliotoxin...
    19 KB (1,718 words) - 19:43, 22 April 2024
  • Thumbnail for Myriocin
    potent than ciclosporin.[citation needed] The multiple sclerosis drug fingolimod was derived from myriocin by using structure–activity relationship studies...
    4 KB (162 words) - 17:25, 1 March 2024
  • corticosteroid responsive. There are also anecdotal reports against using fingolimod or alemtuzumab. Residual disability develops in 50–80% of patients, with...
    27 KB (2,799 words) - 09:09, 23 October 2024
  • Thumbnail for Immunosuppressive drug
    in combination with ciclosporin or tacrolimus in transplant patients. Fingolimod is a synthetic immunosuppressant. It increases the expression or changes...
    29 KB (3,378 words) - 02:54, 25 September 2024
  • Thumbnail for Lysophosphatidylcholine
    5541 CYM-50260 CYM-50308 Dihydro-S1P (sphinganine 1-phosphate) Fingolimod Fingolimod phosphate KRP-203 Mocravimod Ozanimod Phyto-S1P Ponesimod RP-001...
    11 KB (1,140 words) - 01:30, 25 March 2024
  • Thumbnail for Siponimod
    on lymphocytes and other cell types. Siponimod may be very similar to fingolimod but preventing lymphopenia, one of its main side effects, by preventing...
    11 KB (798 words) - 20:58, 10 October 2024
  • Thumbnail for Sphingolipid
    Sphingosyl phosphatide Chun J, Hartung HP (2010). "Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis". Clinical Neuropharmacology. 33 (2): 91–101...
    25 KB (2,774 words) - 16:47, 24 September 2024
  • filipin (INN) Filspari Filsuvez fimasartan (INN) Finacea finasteride (INN) fingolimod (USAN) Finlee Fioricet Fiorinal fipexide (INN) firategrast (USAN, INN)...
    2 KB (191 words) - 04:22, 2 July 2024
  • Thumbnail for Novartis
    Galvus (vildagliptin) Diabetes mellitus type 2 910 2012 39% Gilenya (fingolimod) Multiple sclerosis 1,195 2012 142% Gleevec/Glivec (imatinib) Oncology...
    144 KB (12,146 words) - 09:25, 31 October 2024
  • Thumbnail for Etrasimod
    5541 CYM-50260 CYM-50308 Dihydro-S1P (sphinganine 1-phosphate) Fingolimod Fingolimod phosphate KRP-203 Mocravimod Ozanimod Phyto-S1P Ponesimod RP-001...
    13 KB (811 words) - 02:32, 12 October 2024
  • Thumbnail for Sphingosine-1-phosphate receptor
    PMID 22264485. Groves, Aran; Kihara, Yasuyuki; Chun, Jerold (2013-05-15). "Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation...
    12 KB (1,266 words) - 08:05, 18 August 2023
  • 5541 CYM-50260 CYM-50308 Dihydro-S1P (sphinganine 1-phosphate) Fingolimod Fingolimod phosphate KRP-203 Mocravimod Ozanimod Phyto-S1P Ponesimod RP-001...
    24 KB (2,392 words) - 23:10, 9 September 2024
  • Olokizumab L04AD01 Ciclosporin L04AD02 Tacrolimus L04AD03 Voclosporin L04AE01 Fingolimod L04AE02 Ozanimod L04AE03 Siponimod L04AE04 Ponesimod L04AE05 Etrasimod...
    3 KB (367 words) - 15:37, 25 January 2024
  • Company, Lilly Icos Erectile dysfunction Nov-2002 2017-Nov 52 Gilenya fingolimod 272,701 4.05% Novartis Corporation Multiple sclerosis Feb-2000 2007-Jan...
    29 KB (281 words) - 06:29, 12 August 2024
  • Thumbnail for Ponesimod
    considered to be too low to be of clinical importance in a study. Like fingolimod, which is already approved for the treatment of multiple sclerosis, ponesimod...
    15 KB (1,066 words) - 21:13, 1 November 2024
  • that certain immunosuppressants used to treat MS—such as interferon-β, fingolimod, natalizumab, and alemtuzumab—worsen NMO disease progression and should...
    68 KB (7,285 words) - 22:42, 21 September 2024
  • studying the safety and efficacy of fingolimod in a comparison with interferon beta-1a, and led to approval of fingolimod by the Food and Drug Administration...
    17 KB (1,734 words) - 06:25, 20 August 2024
  • Diroximel fumarate Efgartigimod alfa (+hyaluronidase) Etrasimod Filgotinib Fingolimod Guselkumab Iptacopan Itacitinib Ixekizumab Netakimab Olokizumab Ozanimod...
    7 KB (299 words) - 13:45, 27 April 2024